Investigation of serum visfatin levels in patients with psoriasis;Psoriasisli hastalarda serum visfatin düzeylerinin araştirilmasi

Turkderm Deri Hastaliklari ve Frengi Arsivi

Volumn 44, Issue 1, 2010, Pages 15-18

  Bozkurt, Nurhal Mercan ^a   Yildirim, Mehmet ^a   Ceyhan, Ali Murat ^a   Kara, Yusuf ^a   Vural, Hüseyin ^a  

^a SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

PASI; Psoriasis; Visfatin

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; HUMAN; MAJOR CLINICAL STUDY; PSORIASIS; SCORING SYSTEM;

EID: 77949440989     PISSN: 1019214X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Erdal E: Psoriasis etyopatogenezi. T Klin J Dermatol 2004;14:11-4.
2. Yazici AC, Karabulut AA: Psoriazisin genetik özellikleri ve patogenezi. Dermatose 2003;2:95-102.
3. Luk T, Malam Z, Marshall JC: Pre-B cell colony enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J Leukoc Biol 2008;83:804-16.
4. Moschen AR, Kaser A, Enrich B et al: Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007;178:1748-58.
5. Tilg H, Moschen AR: Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci (Lond) 2008;114:275-88.
6. Pilz S, Mangge H, Obermayer-Pietsch B, März W: Visfatin/pre-B-cell colony-enhancing factor: a protein with various suggested functions. J Endocrinol Invest 2007;30:138-44.
7. Hug C, Lodish HF: Visfatin: a new adipokine. Science 2005;307:366-7.
8. Oki K, Yamane K, Kamei N, Nojima H, Kohno N: Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clin Endocrinol 2007;67:796-800.
9. Kendal CE, Bryant-Greenwood GD: Pre-B-cell colony-enhancing factor (PBEF/Visfatin) gene expression is modulated by NF-kappaB and AP-1 in human amniotic epithelial cells. Placenta 2007;28:305-14.
10. Otero M, Lago R, Gomez R et al: Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:1198-201.
11. Brentano F, Schorr O, Ospelt C et al: Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum 2007;56:2829-39.
12. Koczan D, Guthke R, Thiesen HJ et al: Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules. Eur J Dermatol 2005;15:251-7.
13. Bilen N: Non-püstüler psoriyazis. T Klin J Int Med Sci 2005;1:22-6.
14. Özden MG, Tekin NS: Psoriazis patogenezinde yenilikler. T Klin J Dermatol 2007;17:112-9.
15. Zhou X, Krueger JG, Kao MCJ et al: Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics 2003;13:69-78.
16. Ergün A: Yaǧ dokusu ve yaǧ hücresi. T Klin J Med Sci 2005;25:412-20.
17. Takematsu H, Tagami H: Lack of correlation between interleukin 6 and interleukin 1 levels in psoriatic lesional skin. Tohoku J Exp Med 1994;172:243-52.
18. Emral R: Adiponektin ve diǧer sitokinler. T Klin J Med Sci 2006;26:409-20.
19. Krasowska D, Pietrzak A, Kàdzielewski J, Lecewicz-Torun B: Plasma concentration of IL-6 and soluble interleukin-6 receptor versus selected acute phase proteins in patients with stationary psoriasis. Med Sci Monit 1998;4:628-32.
20. Mizutani H, Ohmoto Y, Mizutani T, Murata M, Shimizu M: Role of increased production of monocytes TNF-alpha, IL-1beta and IL-6 in psoriasis: relation to focal infection, disease activity and responses to treatments. J Dermatol Sci 1997;14:145-53.
21. Strober B, Teller C, Yamauchi P et al: Effects of etanercept on Creactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol 2008;159:322-30.
22. Kaur S, Zilmer K, Kairane C, Kals M, Zilmer M: Clear differences in adiponectin level and glutathione redox status revealed in obese and normal-weight patients with psoriasis. Br J Dermatol 2008;159:1364-7.
23. Fonseca-Alaniz MH, Takada J, Alonso-Vale MI, Lima FB: Adipose tissue as an endocrine organ: from theory to practice. J Pediatr 2007;83:192-203.
24. Chodorowska G: Plasma concentrations of IFN-gamma and TNF-alpha in psoriatic patients before and after local treatment with dithranol ointment. J Eur Acad Dermatol Venereol 1998;10:147-51.
25. Borská L, Fiala Z, Krejsek J et al: Selected immunological changes in patients with Goeckerman's therapy TNF-alpha, sE-selectin, sP-selectin, sICAM-1 and IL-8. Physiol Res 2006;55:699-706.
26. Mussi A, Bonifati C, Carducci M et al: Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents 1997;11:115-8.
27. Tsiotra PC, Tsigos C, Yfanti E et al: Visfatin, TNF-alpha and IL-6 mRNA expression is increased in mononuclear cells from type 2 diabetic women. Horm Metab Res 2007;39:758-63.
28. Kralisch S, Klein J, Lossner U et al: Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 2005;289:586-90.
29. Kralisch S, Klein J, Lossner U et al: Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes. J Endocrinol 2005;185:1-8.
30. Chodorowska G, Wojnowska D, Juszkiewicz-Borowiec M: C-reactive protein and alpha2-macroglobulin plasma activity in medium-severe and severe psoriasis. J Eur Acad Dermatol Venereol 2004;18:180-3.